Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.

Xbrane Biopharma AB (publ)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

George Rathmann

Amgen Inc.

Sadara Chemical Company is involved in the chemical industry, utilizing new technologies to create a variety of chemicals and additives, including but not limited to amines, glycols, polyurethanes, and polyethylene. It operates in Saudi Arabia and offers products utilized in various sectors such as packaging, personal care, automotive, and oil and gas.

Sadara Chemical Company

Xbrane Biopharma develops biosimilars for the treatment of macular degeneration, rheumatoid arthritis, psoriasis, and cancer with a focus on making biological drugs more accessible. Self-described as a biosimilar developer.

Metric
Company Name	Xbrane Biopharma AB (publ)	Amgen Inc.	Sadara Chemical Company
Symbol	XBRANE	AMGN
MSH ID	COM:XBRANE	COM:AMGEN	COM:SADARA
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Basic Materials & Materials
Industry	Biotechnology	Drug Manufacturers - General	Chemicals
Country	SE	US	SA
Stage
Employee Count	75	26.70K
Website	xbrane.com	amgen.com	sadara.com
LinkedIn		amgen
Founders

Metric
Market Cap	31.03M	172.56B
Enterprise Value
Monthly Web Traffic		1.00M
Web Traffic Growth		-0.02
Valuation
Raised Capital		28.50B

Metric
Revenue	21.84M	28.19B
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.24M	19.74B
EBITDA	-25.32M	7.90B
Operating Income	-28.40M	7.90B
Net Income	-35.52M	6.72B
EPS	-0.14	12.56
Diluted EPS	-0.14	12.49
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.39	0.70
Operating Profit Margin	-1.34	0.32
EBITDA Margin	-1.16	0.28
Net Profit Margin	-1.63	0.24
Return on Equity	-1.22	1.03
Return on Assets	-0.48	0.07
Return on Capital Employed	-0.66	0.12

XBRA

COM:XBRANE

Xbrane Biopharma

Last Close

0.19

25/11 09:39

Market Cap

339.03M

Beta: -

Volume Today

1.80M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.14	22.81
P/B Ratio	0.13	22.55
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.83	6.11
EV Multiple	-0.33	12.57

Metric
Days Sales Outstanding		83.59
Days Payables Outstanding	94.51	69.95
Days Inventory Outstanding	663.73	411.08
Operating Cycle	1.36K	513.92
Cash Conversion Cycle	1.07K	445.24
Asset Turnover	0.37	0.34

Metric
Operating Cash Flow	-37.21M	8.47B
Free Cash Flow	-38.74M	7.36B
Cash Flow to Debt	-2.15	0.13
Operating Cash Flow/Sales	-1.70	0.30
Free Cash Flow Yield	-11.04	0.06

Metric
Cash & Equivalents	5.98M	10.94B
Accounts Receivable	-7.79M	-1.01B
Inventory	9.78M	9.52B
Goodwill		18.63B
Debt to Capitalization	0.52	0.93
Debt to Assets	0.27	0.67
Current Ratio	1.75	2.86
Quick Ratio	1.43	1.62

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.03
R&D to Revenue	1.49	0.17
SG&A to Revenue	0.22